阿斯利康 (AstraZeneca) 以高达 10.5 亿美元收购 Amolyt Pharma，增强其罕见疾病产品组合。 AstraZeneca acquires Amolyt Pharma for up to $1.05bn, bolstering its rare diseases portfolio.

阿斯利康 (AstraZeneca) 将以高达 10.5 亿美元的价格收购临床阶段生物制药公司 Amolyt Pharma。 AstraZeneca to acquire Amolyt Pharma, a clinical-stage biopharmaceutical firm, for up to $1.05bn. 该交易涉及预付款 8 亿美元，并有可能在达到指定里程碑后额外支付 2.5 亿美元。 The deal involves an upfront payment of $800m, with the potential for an additional $250m upon achieving a specified milestone. Amolyt 的重点是治疗罕见内分泌疾病的肽，其中 enboparatide 处于治疗甲状旁腺功能减退症的第三阶段。 Amolyt's focus is on therapeutic peptides for rare endocrine diseases, with eneboparatide in Phase 3 for hypoparathyroidism. 此次收购预计将增强阿斯利康的罕见疾病产品组合，并于 2024 年第三季度完成，具体取决于条件和监管部门的批准。 The acquisition is expected to bolster AstraZeneca's rare diseases portfolio and close by Q3 2024, subject to conditions and regulatory clearances.